INTRODUCTION
The non-ischaemic forearm exercise test (NIFET, also known as the grip test) is often used as a screening test for metabolic myopathies in patients with exercise intolerance, exercise-induced cramps and myalgia. It has been proven to be a very sensitive and specific tool for the detection of McArdle's disease (glycogen storage disease type V (GSDV)). The combination of a blunted increase in lactate (La) (ΔLa<0.8 mmol/L) and large increase in ammonia (NH 3 ) (ΔNH 3 >40 mmol/L) results in a sensitivity and a specificity of 100% and 99.7%, respectively, for this disease. 1 However, the same biochemical profile may occasionally be observed in patients with glycogenosis type III. Another subgroup of patients presents with a high ammonia response along with a normal or mildly blunted lactate response, and the clinical relevance of this isolated hyperammonaemia during the NIFET is largely unknown. [1] [2] [3] [4] [5] The basic principles of ammonia production in muscle have already been well described. 6 During short intense exercise, ammonia is produced predominantly by the deamination of AMP into inosine monophosphate by the enzyme adenylate deaminase in the purine nucleotide cycle. AMP is itself produced by ATP and ADP hydrolysis during energy production for muscle contraction. In glycogen storage diseases, hyperammonaemia is most likely caused by an exaggerated AMP deamination due to deregulation of adenine nucleotides, which causes exercise intolerance due to a critical shortage of ATP. 4 However, the level of production of ammonia, which would be indicative of a muscle disease, remains to be determined.
The primary aim of this study was to systematically analyse the clinical features and the diagnostic results of patients who showed a high ammonia response during the NIFET. In addition, the extent of hyperammonaemia was analysed to determine if it could be used as a screening tool to identify metabolic myopathies.
MATERIALS AND METHODS
All of the patients who performed NIFET between 1999 and 2015 (n=1440) at the Institute of Myology (Pitié-Salpêtrière Hospital, Paris) were included in this study. Many of them also underwent several additional investigations including neurological examination, cardiorespiratory evaluation, nerve conduction studies and electromyography (ENMG), muscle imaging with either CT scan or MRI, muscle biopsy with immunochemistry, western blot, respiratory chain analysis and molecular analysis. Normal values were derived from 60 healthy controls aged between 23 and 58 years (see table 3 in Hogrel et al 2015 1 ). The NIFET protocol has previously been described. 7 Briefly, it consists of a 30 s isometric grip contraction sustained at 70% of the maximal grip strength after which blood samples are taken at 1, 2, 3, 4, 6 and 10 min. Lactate and ammonia are measured according to standardised procedures 1 and compared with baseline values. In controls (n=60), the mean increase in the level of ammonia between resting and peak values was 42.8 ±25.9 mmol/L. After testing the distribution in the levels of ammonia rise for normality (KolmogorovSmirnov test, p>0.1), hyperammonaemia was defined as ΔNH 3 ≥94 mmol/L corresponding to the upper reference limit (URL) computed as 2 SDs above the mean of the control population. Computing this threshold from log transformed data yielded the same value.
All patients with hyperammonaemia were selected and classified according to their increase in lactate using the previously described threshold: 1 ΔLa≤0.8 mmol/L and ΔLa>0.8 mmol/L. In patients with unexplained hyperammonaemia, we reviewed the medical files for data about medical history, neurological examination, ENMG, muscle imaging, muscle biopsy, molecular analysis and possible subsequent diagnosis. Next, if considered appropriate, additional tests were performed by the metabolic neuromuscular specialist in line with our current local diagnostic guidelines. These tests included enzyme assays for glycogenolysis/glycolysis defects (two patients), respiratory chain analysis (three patients), genetic analysis of the mitochondrial DNA (five patients), gene sequencing panels (eight patients) and immunohistochemistry/ immunoblotting on muscle biopsy (one patient).
Subsequently, we assessed the NIFET results and final diagnosis of all patients with hyperammonaemia to determine if a high ammonia response could be used as a screening tool to detect unusual metabolic myopathies.
RESULTS
Out of 1440 patients, 110 patients (7.6%) with hyperammonaemia (ΔNH 3 ≥94 mmol/L) were identified (figure 1). All patients with a small increase in lactate (ΔLa≤0.8 mmol/L) were diagnosed with either McArdle disease (GSDV) (n=32) or a debranching enzyme deficiency (GSD type III (GSDIII)) (n=1). Of the patients with a normal increase in lactate (ΔLa>0.8 mmol/L; n=77), only eight were diagnosed at the beginning of the retrospective analyses with GSDIII (n=4), phosphorylase-b kinase deficiency (GSD type IX (GSDIX)) (n=1), phosphoglucomutase-1 deficiency (GSD type XIV) (n=2) and mitochondrial myopathy related to mitochondrial encephalomyopathy, lactate acidosis and stroke-like episodes (MELAS) mutation (n=1). Additional diagnostic tests have so far resulted in a definitive diagnosis for five additional patients: GSDIII (n=1), GSDIX (n=1), limb girdle muscular dystrophy type 2B (LGMD2B) (n=1), limb girdle muscular dystrophy type 2I (LGMD2I) (n=1) and RYR1-related myopathy (RYR1: ryanodine receptor 1) (n=1). Ammonia levels at rest were not significantly different between controls (24.3±12.0 mmol/L) and patients (26.3±11.9 mmol/L) (unpaired t-test, p=0.304).
Subsequently, we divided the cohort of patients with hyperammonaemia into two subgroups: the first with mild hyperammonaemia (between 1 and 1.5 URL: 94-141 mmol/L; n=72); and a second group with severe hyperammonaemia (>1.5 URL: >141 mmol/L; n=38). All but one of the patients in the latter group (with a RYR1 mutation) were diagnosed with a glycogenosis (82%) (figure 2). Among the six remaining undiagnosed patients, three presented an exaggerated lactate response. Hence, most of the patients without or with other diagnoses were in the mild hyperammonaemia group.
DISCUSSION
The main findings of this retrospective study on ammonia response during the NIFET in a large patient cohort referred for exercise intolerance are: (1) severe postexercise hyperammonaemia (NH 3 >141 mmol/L) points towards a diagnosis of glycogenosis in more than 80% of the patients, even when the production of lactate remains within the normal range; (2) mild postexercise hyperammonaemia (94<ΔNH 3 <141 mmol/L) is a major hallmark of muscle glycogenosis especially when the lactate production is decreased and (3) mild hyperammonaemia (94<ΔNH 3 <141 mmol/L) associated with normal lactate increase and without abnormalities of conventional diagnostic tests (muscle imaging, ENMG and/or muscle biopsy) is likely to be physiological.
Future diagnostic studies should take into account the absolute increase in ammonia (ΔNH 3 ) and consider the NH 3 peak alone or the area under the concentration-time curve to define hyperammonaemia. Furthermore, in the group of patients with mild hyperammonaemia (94-141 mmol/L), many had no abnormalities on other complementary investigations. We therefore suggest that the cut-off value for hyperammonaemia should be higher than 94 mmol/L, while in our study, we used 141 mmol/L.
A limitation of this study is its retrospective nature with some of the patient data being up to 15 years old. Thus, it was Figure 1 Diagnostic flowchart of the hyperammonaemia cohort (ΔNH 3 >94 mmol/L). From the 1440 patients in the database, 110 were identified as having hyperammonaemia. This population was divided in two groups based on the lactate response after the non-ischaemic forearm exercise test. All patients with a small increase in lactate (ΔLa≤0.8 mmol/L) were diagnosed with either a glycogen storage disease type V (GSDV) or a GSD type III (GSDIII). Of the patients with a normal increase in lactate (ΔLa>0.8 mmol/L), only 13/77 have been diagnosed. GSDIX, glycogen storage disease type IX; GSDXIV, glycogen storage disease type XIV; Mito, mitochondriopathy; LGMD, limb girdle muscular dystrophy; RYR1, RYR1-related myopathy. Figure 2 Diagnostic flowchart for patients presenting with severe hyperammonaemia (ΔNH 3 >141 mmol/L). From the 1440 patients in the database, 38 were identified as having severe hyperammonaemia (upper reference limit is >1.5). In this later group, 82% were diagnosed with a glycogen storage disease (GSD). GSDIII, glycogen storage disease type III; GSDV, glycogen storage disease type V; GSDIX, glycogen storage disease type IX; GSDXIV, glycogen storage disease type XIV; RYR1, RYR1-related myopathy.
sometimes impossible to obtain information regarding the clinical course to confirm that no new symptoms had occurred, the molecular analysis or possible diagnosis confirmed later during the follow-up in another medical centre. Therefore, we cannot ascertain that our conclusion concerning the non-specificity of hyperammonaemia is accurate. The growing development of exome-sequencing technology in the near future should allow us to look for new genes implicated in as yet unknown metabolic pathways involved in hyperammonaemia.
Severe hyperammonaemia at NIFET (ΔNH 3 >141 mmol/L) should always bring one's attention towards a diagnosis of muscle glycogenosis, and genetic testing of PYGM (geneencoding myophosphorylase) should be performed first. Assessment of blood debranching enzyme activity should be done if the patient also presents with hepatomegaly and/or hypoglycaemic episodes. This study also showed that mild hyperammonaemia (ΔNH 3 between 94 and 141 mmol/L) may occur in a few patients with muscular dystrophies and mitochondrial myopathy, but this anomaly is probably coincidental as it was also observed in 4 of the 60 control subjects (unpublished data).
In conclusion, severe postexercise hyperammonaemia (ΔNH 3 >141 mmol/L), even in the presence of a normal lactate response, is strongly suggestive of a muscle glycogenosis as no other metabolic myopathy could be identified so far. Mild hyperammonaemia in the absence of abnormalities on other tests is most likely non-specific and not indicative of a disease.
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